Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
UBS
Accenture
Medtronic
Argus Health
Fuji
Teva
Chinese Patent Office
Daiichi Sankyo

Generated: February 23, 2018

DrugPatentWatch Database Preview

Omacetaxine mepesuccinate - Generic Drug Details

« Back to Dashboard

What are the generic sources for omacetaxine mepesuccinate and what is the scope of omacetaxine mepesuccinate freedom to operate?

Omacetaxine mepesuccinate
is the generic ingredient in one branded drug marketed by Teva Pharms Intl and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Omacetaxine mepesuccinate has forty-nine patent family members in nineteen countries.

There are two drug master file entries for omacetaxine mepesuccinate. One supplier is listed for this compound.
Summary for omacetaxine mepesuccinate

US Patents and Regulatory Information for omacetaxine mepesuccinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for omacetaxine mepesuccinate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,613,900 Cephalotaxane derivatives and process for their preparation ➤ Sign Up
7,842,687 Cephalotaxane derivatives and their processes of preparation and purification ➤ Sign Up
6,831,180 Cephalotaxane derivatives and process for their preparation ➤ Sign Up
7,169,774 Cephalotaxane derivatives and their processes of preparation and purification ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for omacetaxine mepesuccinate

Country Document Number Estimated Expiration
Canada 2324895 ➤ Sign Up
Australia 2002304338 ➤ Sign Up
Portugal 1064285 ➤ Sign Up
Japan 2004523586 ➤ Sign Up
Japan 2002507615 ➤ Sign Up
Japan 4942871 ➤ Sign Up
Japan 2005508896 ➤ Sign Up
Turkey 200003613 ➤ Sign Up
Denmark 1064285 ➤ Sign Up
Japan 2009132735 ➤ Sign Up
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Mallinckrodt
UBS
Medtronic
Julphar
Dow
Cerilliant
Chubb
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot